Seniors Integrated Longitudinal cardioVascular Evaluation of Coronary Heart Disease: a Multicenter, Prospective Registry in China (SILVER-China)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Coronary Arterial Disease (CAD), ELDERLY PEOPLE. Basic parameters: from 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study aims to establish a nationwide cohort and biobank of elderly patients with coronary heart disease (CHD) and to develop risk prediction models and clinical treatment optimization plans based on this data. The specific research content is as follows: The Study plan to continuously enroll hospitalized elderly CHD patients across 50 centers nationwide. Using networked electronic data collection technology, standardized methods and protocols will be used to gather demographic information (such as age, gender, education level, income, etc.), clinical information (medical history, past treatment records, current treatment plans, surgical records, medication use, etc.), lifestyle information (dietary habits, exercise frequency, smoking, drinking, etc.), biological information (such as inflammatory markers, etc.), and physical examination data (such as blood pressure, ECG, sleep monitoring, imaging examinations, etc.). These patients will be followed up long-term (1 month, 6 months, 1 year, and annually thereafter for up to 5 years) to establish a database that meets international standards. Centers meeting the criteria will also retain biological samples, creating a multicenter biobank for elderly CHD patients. Second, based on the established clinical cohort, a risk prediction model for elderly CHD patients will be developed, including mortality risk, ischemic risk, bleeding risk, etc. Additionally, optimized clinical diagnostic and treatment plans will be formulated to improve the treatment outcomes and quality of life for elderly CHD patients. This research is expected to provide scientific evidence and technical support for the prevention, diagnosis, and treatment of CHD in elderly patients.
Primary outcome measures
- major adverse cardiovascular events [Time frame: From enrollment to the end of follow up at 5 years]
Secondary outcome measures (11)
- all-cause mortality [Time frame: From enrollment to the end of follow up at 5 years]
- cardiogenic death [Time frame: From enrollment to the end of follow up at 5 years]
- non-fatal myocardial infarction [Time frame: From enrollment to the end of follow up at 5 years]
- non-fatal stroke and ischemia-driven revascularization [Time frame: From enrollment to the end of follow up at 5 years]
- stent thrombosis [Time frame: From enrollment to the end of follow up at 5 years]
- major bleeding [Time frame: From enrollment to the end of follow up at 5 years]
- all BARC bleeding [Time frame: From enrollment to the end of follow up at 5 years]
- NACE [Time frame: From enrollment to the end of follow up at 5 years]
- Quality of life [Time frame: From enrollment to the end of follow up at 5 years]
- angina pectoris readmission [Time frame: From enrollment to the end of follow up at 5 years]
- heart failure [Time frame: From enrollment to the end of follow up at 5 years]
Eligibility criteria
Inclusion criteria
① Age requirements: Participants are ≥ 75 years old;
- This time he was admitted to the hospital due to angina pectoris and other coronary heart disease-related symptoms
③ Conform to the diagnosis of coronary heart disease: meet any one of the following conditions:
- This admission was performed for coronary angiography, coronary artery CTA confirmed coronary heart disease;
- Previous clear coronary angiography, coronary artery Coronary heart disease diagnosed by imaging evidence such as CTA evidence;
- The attending physician according to the patient's symptoms, medical history, myocardial injury markers, electrocardiogram, echo cardiography, myocardial radionuclide imaging, etc. diagnosed coronary heart disease.
④ Informed consent: Participants must be able to understand the content of the study, voluntarily participate in the study, and sign the informed consent form.
Exclusion criteria
- Combined with severe non-cardiovascular disease: life expectancy does not exceed 6 months, such as advanced cancer or other end-stage disease;
- Unable to cooperate with long-term follow-up: such as patients with severe cognitive impairment or severe mental illness; ③ Non-cardiogenic death within 24 hours after admission.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Beijing Hospital — Beijing
Identifiers
NCT: NCT06880575 · BJ-2024-140 · BJ-2024-140